Refractory Squamous Cell Carcinoma of the Conjunctiva Treated With Subconjunctival Ranibizumab (Lucentis): A Two-Year Study

Ophthalmic Plastic and Reconstructive Surgery, 05/15/2012

This 2–year study demonstrated that subconjunctival ranibizumab induced regression of squamous cell carcinoma of the conjunctiva and cornea. Therefore, antivascular endothelial growth factor chemotherapy may offer a new strategy, complement excision and cryotherapy, or provide an alternative to radiation and/or exenteration. Further, larger investigations utilizing a larger group of patients are needed to determine the ideal dose, route of drug delivery, and case selection.

Print Article Summary Cat 2 CME Report